PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta” or the “Company”) (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024.
- Roquette Announces a New Organization following the Acquisition of IFF Pharma Solutions - May 5, 2025
- Contract for financing the construction of the final stage of the Uus-Järveküla residential area and profit distribution to fund investors - May 5, 2025
- VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - May 5, 2025